Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04795323 · ClinicalTrials.gov registry record · Phase 2

Proof of Concept Study Assessing Technology-Assisted Respiratory Adherence Prototype Version 3 in Individuals With COPD

A Phase 2 study of Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim.

Completed
Registry status
Phase 2
Development phase
5
Enrollment target
2
Study locations

NCT04795323: Completed Phase 2 study of Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim.

NCT04795323 is a Phase 2 study of Pulmonary Disease, Chronic Obstructive that has completed, run by Boehringer Ingelheim. The registered enrollment target is 5 participants, below the 1,044-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04795323, a Phase 2 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by Boehringer Ingelheim.

COMPLETED
Registry status
Phase 2
Development phase
5 participants
Enrollment target
2
Study locations

Study Summary

The study's primary aim is to assess whether there is a clinically significant reduction in breathlessness in symptomatic individuals with chronic obstructive respiratory disease (IwCOPD) following engagement with Technology-Assisted Respiratory Adherence prototype 3. The study's secondary aim is to assess whether there is an associated maintenance or increase in activities of daily living to support a positive benefit of Technology-Assisted Respiratory Adherence prototype 3 on breathlessness and whether there is an improvement in the physical activity experience of the patient.

Primary Outcome

The CRQ-SAI questionnaire first asks participants to mark important, frequent activities that made them feel out of breath during the last 2 weeks; they can select these activities from a list, and they can also add additional activities to the list. Participants are then asked to select the most important activities from the list, up to a maximum of 5 activities. Next, for each of these activities, which correspond to questions 1-5, the participants will mark their level of shortness of breath;

Interventions

  • DEVICE TARA v3.1, only non-pharmacological self-management support
  • DEVICE TARA v3.2, both non-pharmacological and pharmacological self-management support

Study Locations (2)

North Carolina

  • Clinical Research of Gastonia - Gastonia

South Carolina

  • Lowcountry Lung and Critical Care - Charleston

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2021-04-08
Est. Completion 2022-03-12
Phase Phase 2
Boehringer Ingelheim

515 total trials

What the finished NCT04795323 record still lists

NCT04795323 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,044-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 2 interventions - of which TARA v3.1, only non-pharmacological self-management support is the first listed.

NCT04795323 reports a single indexed study location in North Carolina, South Carolina.

Frequently Asked Questions

What is clinical trial NCT04795323 about?

NCT04795323 is a clinical study titled "Proof of Concept Study Assessing Technology-Assisted Respiratory Adherence Prototype Version 3 in Individuals With COPD". The study's primary aim is to assess whether there is a clinically significant reduction in breathlessness in symptomatic individuals with chronic obstructive respiratory disease (IwCOPD) following engagement with Technology-Assisted Respiratory Adherence prototype 3. The study's secondary aim is t...

What is the current status of trial NCT04795323?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2021-04-08. Estimated completion is 2022-03-12.

What conditions does trial NCT04795323 study?

This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.

What interventions are being tested in trial NCT04795323?

The interventions under investigation include: TARA v3.1, only non-pharmacological self-management support (DEVICE), TARA v3.2, both non-pharmacological and pharmacological self-management support (DEVICE).

Who is sponsoring clinical trial NCT04795323?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04795323 being conducted?

This trial has 2 study locations across North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pulmonary Disease, Chronic Obstructive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04795323's enrollment target sits among peer trials

5 75th of 74 the lowest of 74 other Pulmonary Disease, Chronic Obstructive trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pulmonary Disease, Chronic Obstructive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04795323, the US trial registry maintained by the National Library of Medicine. NCT04795323 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.